Preventive cardiology: Quo vadis?
Authors:
Hana Rosolová
Authors‘ workplace:
Centrum preventivní kardiologie 2. interní kliniky FN a LFUK v Plzni
Published in:
Vnitř Lék 2023; 69(2): 76-81
Category:
Main Topic
doi:
https://doi.org/10.36290/vnl.2023.014
Overview
Reflections of preventive cardiology history, it´s development and look to the future are mentioned. The main problems of primary and secondary prevention for atherosclerotic cardiovascular diseases are presented. New ways to the prevention improvement are sketched in the field of physician care, inside the whole society and throught the new technologies.
Keywords:
preventive cardiology – life style – risk factors for atherosclerosis – primary and secondary prevention
Sources
1. Damon A, Damon ST, Harpending HC, et al. Predicting coronary Heart disease from body measurement of Framingham males. J Chron, DiS. 1969;21:781-802.
2. Conroy RM, Pyörälä K, Fitzgerald AO, et al. Examination od ten‑year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Europ Heart J. 2021; doi:10.1093/eurheartj/ehab484.
4. Rosolová H, et al. Preventivní kardiologie v kostce. Axonite CZ, Praha 2013.
5. Šatný M, Vrablík M. LIPIcontrol 2 aneb co se změnilo po 3 letech. AtheroRev. 2020;5(3):185-90.
6. Šatný M, Tůmová E, Vrablík M, et al. Studie LipitenCliDec – profil pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v primární péči v Česku: výsledky 2. fáze. AtheroRev. 2020;5(2):117-23.
7. Chrástek J, Šobra J, Stolz I, Rosolová H. Výskyt rizikových faktorů ischemické choroby srdeční během pětileté činnosti lázeňského ústavu. Prakt. Lék. 1995;75:15-17.
8. Rosolová H, Chrástek J, Zikmund M, et al. Non‑pharmacological control of blood pressure and physical fitness in subjects with arterial hypertension. Cor Vasa. 1991;33:123-131.
9. De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC‑EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019 Jun;285:135-146.
10. Bruthans J, Cífková R, Lánská V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol. 2014 Jul;21(7):829-39.
11. Národní kardiovaskulární program České republiky. Koncepce prevence, diagnostiky, léčby a výzkumu kardiovaskulárních chorob v České republice (www.kardio‑cz. cz).
12. Piepoli M, Abreu A, Albus C, et al. Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology od the ESC. Eur J Prev Cardiol. 2020;27:181-205.
13. Tikkanen E, Gustafsson S, Ingelsson E. Associations of fitness, physical activity, strength, and genetic risk with cardiovascular disease: Longitudinal analyses in the UK Biobank Study. Circulation. 2018;137:2583-2591.
14. Said MA, Verweij N, van der Harst P. Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the UK Biobank Study. JAMA Cardiol. 2018;3:693-702.
Labels
Diabetology Endocrinology Internal medicine CardiologyArticle was published in
Internal Medicine
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/6b02e7f9de5550025f86ad96baaf3ba0.jpg)
2023 Issue 2
Most read in this issue
- News in diagnostics and treament of cardiomyopathies
- New perspectives in the treatment of chronic heart failure
- News in immunology
- The impact of uncontrolled hypertension on the CNS